Stuart Ashman Discusses Croda PLC – SkinBiotix® Agreement
Stuart Ashman Discusses Winclove – AxisBiotix® Agreement
Stuart Ashman CEO at AJ Bell Investor Evening
Chief Science Officer discusses Human Study Results
Professor Cath O’Neil named one of top movers in bio industry
Trade shows and seminars
Full list of trade shows and seminars 2020
Professor Cath O’Neil Shares Magazine event 2018
Half year results
Manchester, UK – 03 March 2020 – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, announces its unaudited half year results for the six months to 31 December 2019.
Operational and financial highlights
- New strategy presented to shareholders, defining five pillars of development and commercial focus
- Signed first commercial agreement in November 2019, with Croda International Plc (“Croda”), using SkinBiotix® as the foundation of an active skincare ingredient
- Post period end, signed a development agreement around the skin-gut axis with Winclove Probiotics B.V. (“Winclove”) to create a specialist probiotic food supplement targeting psoriasis
- Loss from operations of £889k (H1 2018: £632k) with increase due to R&D and operating expenditure
- Cash as at 31 December 2019 £2.5m (30 June 2019: £3.1m), in line with management’s expectations